ARIH1 and neoplasm: In accordance with the previous report14, cisplatin treatment resulted in a significant increase in intracellular and intratumoral ARIH1 levels (Fig. 1f, g, Supplementary Fig. 3), indicating that ARIH1 may participate in enhancing anti-tumor T-cell immunity in the combination group.